Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Fanconi Anemia, Complementation Group D1 1

Interventions

pembrolizumab 9trastuzumab deruxtecan 5trametinib 4dabrafenib 4zanubrutinib 3nilotinib 3fludarabine 3Trastuzumab 3Dexamethasone 3Cyclophosphamide 3tucatinib 2tisagenlecleucel 2selinexor 2relatlimab 2pemigatinib 2larotrectinib 2ipatasertib 2erdafitinib 2entrectinib 2enfortumab vedotin 2defactinib 2daratumumab 2blinatumomab 2binimetinib 2belzutifan 2axicabtagene ciloleucel 2atezolizumab 2TIC10 compound 2Sunitinib 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × olaparib × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡